Samrat Pharmachem Ltd (SAMRATPH) is currently trading at 233.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Samrat Pharmachem Limited, established in 1992, primarily manufactures and sells chemicals. A key development was the creation of a subsidiary, Samrat Remedies Limited, focusing on pharmaceutical bulk drugs and chemicals. The company leverages its long-standing experience in chemical manufacturing to expand into pharmaceuticals, a strategic move for diversification. Their operational strategy includes advancing their pharmaceutical segment, aiming to capture a larger market share in the industry.

Over the past 52 weeks, Samrat Pharmachem Ltd has traded between a low of ₹190.00 and a high of ₹333.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Samrat Pharmachem Ltd has a market capitalization of approximately 71.31. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Samrat Pharmachem Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -32.27 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 71.31 Cr, Samrat Pharmachem Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Samrat Pharmachem Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Samrat Pharmachem Ltd is -32.27. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.